SCHEMBL6353539

SCHEMBL6353539

CCC(=O)Nc1cccc(B(O)O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.63
POLB P06746 2/20 0.63
NR4A1 P22736 1/20 0.63
NLRP3 Q96P20 1/20 0.62
GAA P10253 2/20 0.61
KMT2A Q03164 5/20 0.58
MEN1 O00255 3/20 0.58
LMNA P02545 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CYP3A4 P08684 4/20 0.52
CYP2C19 P33261 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
CYP2D6 P10635 2/20 0.52
MAPT P10636 2/20 0.51
ALDH1A1 P00352 4/20 0.51
MAPK1 P28482 1/20 0.51
F2R P25116 1/20 0.51
CYP1A2 P05177 2/20 0.50
NPC1 O15118 2/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15985297 0.87 NLRP3 (0.59) NLRP3MAPTALDH1A1MAPK1F2R
SCHEMBL21788534 0.84 RAB9A (0.56) RAB9APOLBNR4A1NLRP3GAA
SCHEMBL10970617 0.84 RAB9A (0.85) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL12377475 0.83 CA1 (0.60) RAB9APOLBNR4A1NLRP3KMT2A
SCHEMBL14756770 0.83 NLRP3 (0.58) RAB9APOLBNR4A1NLRP3GAA
SCHEMBL7744399 0.83 NLRP3 (0.58) RAB9APOLBNR4A1NLRP3GAA
SCHEMBL8622297 0.83 NLRP3 (0.58) RAB9APOLBNLRP3KMT2AMEN1
SCHEMBL23169416 0.83 LMNA (0.58) RAB9APOLBNLRP3KMT2AMEN1
SCHEMBL6332545 0.83 KMT2A (0.68) RAB9APOLBNLRP3GAAKMT2A
SCHEMBL20605366 0.83 NLRP3 (0.65) NLRP3KMT2AMEN1L3MBTL1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS PROTOMER TECHNOLOGIES, INC. 2023-05-04 US disclosed
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS PROTOMER TECHNOLOGIES, INC. 2023-05-04 US disclosed
US-20210369815-A1 GLUCOSE RESPONSIVE INSULINS PROTOMER TECHNOLOGIES, INC. 2021-12-02 US disclosed
US-11052133-B2 Glucose responsive insulins PROTOMER TECHNOLOGIES, INC. (US) 2021-07-06 US disclosed
US-20200268291-A1 MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION SENSEONICS, INCORPORATED (US) 2020-08-27 US disclosed
US-10683379-B2 Polymers, hydrogels, and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-06-16 US disclosed
WO-2020045342-A1 PRETREATMENT REAGENT, AND NANOPARTICLE ANALYSIS AND RECOVERY METHOD 国立大学法人東京大学 2020-03-05 WO disclosed
US-20190329187-A1 AFFINITY POLYMERS AND METHODS FOR REDUCING PURINE LEVELS IN COMPLEX MIXTURES NITTO DENKO CORPORATION (JP) 2019-10-31 US disclosed
US-20190247468-A1 GLUCOSE RESPONSIVE INSULINS PROTOMER TECHNOLOGIES, INC. 2019-08-15 US disclosed
US-9732101-B2 Bioreversible boronates for delivery of molecules into cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2017-08-15 US disclosed
US-20160083706-A1 BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-24 US disclosed
US-20160024122-A1 BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed
US-9234048-B2 Boronate-mediated delivery of molecules into cells WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-01-12 US disclosed
WO-2015106292-A1 BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2015-07-16 WO disclosed
WO-2015081280-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION COFERON, INC. (US) 2015-06-04 WO disclosed
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
US-20130196433-A1 Boronate-Mediated Delivery of Molecules into Cells WISCONSIN ALUMNI RESEARCH FOUNDATION 2013-08-01 US disclosed
WO-2013033270-A2 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2013-03-07 WO disclosed
US-6919382-B2 Preparation and uses of conjugated solid supports for boronic acids THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2005-07-19 US disclosed
US-20030044840-A1 Preparation and uses of conjugated solid supports for boronic acids GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052133-B2 Glucose responsive insulins GLP1R, GPR119, IAPP RAB9A 3133/4885POLB 4856/4885NR4A1 1106/4885
US-20190247468-A1 GLUCOSE RESPONSIVE INSULINS GLP1R, GPR119, IAPP RAB9A 3133/4885POLB 4856/4885NR4A1 1106/4885
US-10683379-B2 Polymers, hydrogels, and uses thereof BOLA2; BOLA2B, PARG, BRAP RAB9A 2827/4885POLB 1465/4885NR4A1 3516/4885
US-20200268291-A1 MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION SLC2A1, SLC2A4, SLC2A3 RAB9A 4008/4885POLB 4764/4885NR4A1 2392/4885
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 RAB9A 4123/4885POLB 1252/4885NR4A1 832/4885
US-20030044840-A1 Preparation and uses of conjugated solid supports for boronic acids SLC43A1, SBDS, SLC7A5 RAB9A 2477/4885POLB 613/4885NR4A1 2015/4885
US-20160024122-A1 BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS BAG6, BCAP31, PHB1 RAB9A 341/4885POLB 1552/4885NR4A1 4050/4885
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS GPR119, GLP1R, IAPP RAB9A 3213/4885POLB 4793/4885NR4A1 3691/4885
US-20130196433-A1 Boronate-Mediated Delivery of Molecules into Cells BCAP31, PHAX, BTD RAB9A 1908/4885POLB 1971/4885NR4A1 3859/4885
US-20210369815-A1 GLUCOSE RESPONSIVE INSULINS GLP1R, GPR119, IAPP RAB9A 3133/4885POLB 4856/4885NR4A1 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.